



DIVISION OF
CORPORATION FINANCE

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

June 15, 2018

Thomas Gad
Founder, Chairman, President and Head of Business Development
Y-mAbs Therapeutics, Inc.
750 Third Avenue
9th Floor
New York, NY 10017

Re: Y-mAbs Therapeutics, Inc.
Amendment No. 2 to Draft Registration Statement on Form S-1
Submitted June 8, 2018
CIK No. 0001722964

Dear Mr. Gad:

We have reviewed your amended draft registration statement and have the following comments. In some of our comments, we may ask you to provide us with information so we may better understand your disclosure.

Please respond to this letter by providing the requested information and either submitting an amended draft registration statement or publicly filing your registration statement on EDGAR. If you do not believe our comments apply to your facts and circumstances or do not believe an amendment is appropriate, please tell us why in your response.

After reviewing the information you provide in response to these comments and your amended draft registration statement or filed registration statement, we may have additional comments.

Amendment No. 2 to Draft Registration Statement on Form S-1

Summary

Overview, page 1

1. We note your revised disclosure regarding topline results from the phase 2 trial reported in May 2018. Where you discuss results from any of your clinical trials in the Summary, please revise to indicate the clinical endpoints and whether the results were observed with statistical significance.

Thomas Gad
Y-mAbs Therapeutics, Inc.
June 15, 2018
Page 2

You may contact Rolf Sundwall at 202-551-3105 or Kevin Vaughn at 202-551-3494 if you have questions regarding comments on the financial statements and related matters. Please contact Ada D. Sarmento at 202-551-3798 or Mary Beth Breslin at 202-551-3625 with any other questions.

Division of Corporation Finance
Office of Healthcare & Insurance

cc: Dwight A. Kinsey